1. Cases of ALK-Rearranged Lung Cancer with 5-Year Progression-Free Survival with Crizotinib as Initial Precision Therapy 
Deepa Rangachari, MD, Xiuning Le, MD, PhD, Meghan Shea, MD, Mark S. Huberman, MD, Paul A. VanderLaan, MD, PhD, Susumu S. Kobayashi, MD, PhD, Daniel B. Costa, MD, PhD 
Journal of Thoracic Oncology 
Volume 12, Issue 11, Pages e175-e177 (November 2017)
DOI: /j.jtho
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

2. Figure 1
Cases with 5 or more years (≥60 months) after initiation of crizotinib in two patients with advanced ALK receptor tyrosine kinase gene-rearranged lung cancers. (A) Computed tomography image of the neck in case 1 before the start and during year 6 of use of crizotinib. Red circle indicates responsive right supraclavicular lymphadenopathy. (B) Computed tomography image of the chest in case 2 before the start and during year 5 of use of crizotinib. Red circles indicate responsive subpectoral lymph nodes. Both patients didn't have brain metastases at diagnosis or during the course of crizotinib therapy.
Journal of Thoracic Oncology  , e175-e177DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

3. Figure 2
Use of anaplastic lymphoma kinase (ALK) inhibitors, anticancer, and palliative therapies for the first 5 years (60 months) after initiation of crizotinib in 26 patients with advanced ALK receptor tyrosine kinase gene (ALK)-rearranged lung cancers. The type of ALK tyrosine kinase inhibitor, chemotherapy, or best supportive care are indicated by different colors. Progressive disease according to the Response Evaluation Criteria in Solid Tumors is indicated by the letter P, toxicity to crizotinib by the letter T, use of radiotherapy by the letter X, loss of patient to follow-up by the letter L, death by the letter D, and ongoing therapy/survival by a plus symbol.
Journal of Thoracic Oncology  , e175-e177DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions

4. Figure 3
Progression-free survival (PFS) and overall survival (OS) of patients with ALK receptor tyrosine kinase gene (ALK)-rearranged lung cancers after initiation of crizotinib. (A) PFS curve with median and yearly estimates. (B) OS curve with median and yearly estimates. Data were collected and managed using the Research Electronic Data Capture system at our institution. Tumor genotyping was performed using an ALK fluorescence in situ hybridization break-apart probe in diagnostic tumor samples. The Response Evaluation Criteria in Solid Tumors was utilized when reviewing target/nontarget radiographic images. PFS and OS were calculated in months (rounded to the nearest full month) from time of initiation of crizotinib. PFS and OS were explored by the Kaplan-Meier method. Statistical analyses and curves were obtained with the GraphPad Prism 6 software (GraphPad Software, La Jolla, CA).
Journal of Thoracic Oncology  , e175-e177DOI: ( /j.jtho )
Copyright © 2017 International Association for the Study of Lung Cancer Terms and Conditions